Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Candidates For The US FDA’s STAR Program Might As Well Be Breakthrough Therapies, Too

Executive Summary

The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.

You may also be interested in...



US FDA/Industry Thinking PDUFA VIII Could Be A Hybrid Negotiation

Virtual meetings proved successful, and could be allowed again when the next round of user fee reauthorization talks convene.

US FDA Grants RMAT Requests At Similar Rate To Breakthrough Designations

Over the first five years of the regenerative medicine advanced therapy designation, analysis by the Pink Sheet finds the 40% success rate of requests is comparable to the broader breakthrough therapy designation, despite less stringent RMAT criteria.

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel